Top

BMC Endocrine Disorders

Published in:

Open Access 01-12-2021 | Type 2 Diabetes | Research article

Association of apolipoproteins A1 and B with type 2 diabetes and fasting blood glucose: a cross-sectional study

Authors: Liang Gao, Yaju Zhang, Xingmin Wang, Hongli Dong

Published in: BMC Endocrine Disorders | Issue 1/2021

Abstract

Background

Apolipoprotein (Apo) may be associated with type 2 diabetes (T2D), however, little is known whether or not serum apolipoproteins are correlated with fasting blood glucose (FBG) and the prevalence of T2D in Chinese populations. In this study, we examined the association of serum ApoA1, ApoB, and the ratio of ApoB/ApoA1 (ApoB/A1 ratio) with T2D and FBG level, and compared apolipoprotein indicators in predicting T2D in Chinese adults.

Methods

A total of 1027 subjects were enrolled in this cross-sectional study. The association of ApoA1, ApoB, and ApoB/A1 ratio with T2D prevalence was determined using logistic regression models. Multivariate-analysis of covariance (ANCOVA) was performed for comparisons of the mean difference in FBG level.

Results

We found that ApoB and ApoB/A1 ratio were positively associated with T2D prevalence and FBG, while inverse association was noted between ApoA1 and T2D prevalence as well as FBG. Stratified analyses for sex, age, body mass index (BMI), smoking, and alcohol consumption showed no significant difference for the association of ApoA1, ApoB, and ApoB/A1 ratio with the prevalence of T2D among subgroups (all p-interactions> 0.05). Nonetheless, ApoA1 poorly performed in predicting T2D as it provided an AUC value of 0.310 that was significantly lower than those observed for ApoB (AUC value: 0.631) and ApoB/A1 ratio (AUC value: 0.685). Finally, path analyses indicated that the association between ApoB and T2D was mediated by BMI.

Conclusions

This study reveals the association of serum ApoA1, ApoB, and ApoB/A1 ratio with T2D and FBG in Chinese adults, suggesting that ApoB and ApoB/A1 ratio may be early indicators for predicting T2D. Prospective investigation in large cohort is needed.

Available only for authorised users

International Diabetes Federation. IDF Diabetes Atlas. 9th edn. Brussels: International Diabetes Federation; 2019. Available from: https://www.diabetesatlas.org/en/resources/.

National Diabetes Research Group. Diabetes mellitus survey of 300,000 in fourteen provinces and cities of China. Chin Med J. 1981;20:678–81.

Yoshino G, Hirano T, Kazumi T. Atherogenic lipoproteins and diabetes mellitus. J Diabetes Complicat. 2002;16(1):29–34. https://doi.org/10.1016/S1056-8727(01)00199-4.CrossRef

Goldberg IJ. Clinical review 124: diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001;86(3):965–71. https://doi.org/10.1210/jcem.86.3.7304.CrossRefPubMed

Seo MH, Bae JC, Park SE, Rhee EJ, Park CY, Oh KW, et al. Association of lipid and lipoprotein profiles with future development of type 2 diabetes in nondiabetic Korean subjects: a 4-year retrospective, longitudinal study. J Clin Endocrinol Metab. 2011;96:2011–1857.CrossRef

Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Wolever TM, et al. Utility of non-high-density lipoprotein cholesterol in assessing incident type 2 diabetes risk. Diabetes Obes Metab. 2012;14(9):821–5. https://doi.org/10.1111/j.1463-1326.2012.01607.x.

Ndumele CE, Matsushita K, Astor B, Virani SS, Mora S, Williams KE, et al. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. Eur J Prev Cardiol. 2014;21(7):866–75. https://doi.org/10.1177/2047487312465523.CrossRefPubMed

Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006;259(3):247–58. https://doi.org/10.1111/j.1365-2796.2006.01616.x.CrossRefPubMed

Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811–22. https://doi.org/10.2337/dc08-9018.

10.

Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994;120(12):1012–25. https://doi.org/10.7326/0003-4819-120-12-199406150-00008.CrossRefPubMed

11.

Sniderman AD, Faraj M. Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Curr Opin Lipidol. 2007;18(6):633–7. https://doi.org/10.1097/MOL.0b013e3282f0dd33.CrossRefPubMed

12.

van der Vorst EPC. High-density lipoproteins and Apolipoprotein A1. Subcell Biochem. 2020;94:399–420. https://doi.org/10.1007/978-3-030-41769-7_16.CrossRefPubMed

13.

Andersen LH, Miserez AR, Ahmad Z, Andersen RL. Familial defective apolipoprotein B-100: A review. J Clin Lipidol. 2016;10(6):1297–302. https://doi.org/10.1016/j.jacl.2016.09.009.CrossRefPubMed

14.

Tang S, Tabet F, Cochran BJ, Cuesta Torres LF, Wu BJ, Barter PJ, et al. Apolipoprotein A-I enhances insulin-dependent and insulin-independent glucose uptake by skeletal muscle. Sci Rep. 2019;9(1):1350. https://doi.org/10.1038/s41598-018-38014-3.

15.

Wu BJ, Sun YD, Ong KL, Li Y, Tang SD, Barter PJ, et al. Apolipoprotein A-I protects against pregnancy-induced insulin resistance in rats. Arterioscler Thromb Vasc Biol. 2019;39(6):1160–71. https://doi.org/10.1161/ATVBAHA.118.312282.

16.

Zhang X, Zhang W, Saraf SL, Nouraie M, Han J, Gowhari M, et al. Genetic polymorphism of APOB is associated with diabetes mellitus in sickle cell disease. Hum Genet. 2015;134(8):895–904. https://doi.org/10.1007/s00439-015-1572-3.

17.

Domingo-Espin J, Nilsson O, Bernfur K, Del Giudice R, Lagerstedt JO. Site-specific glycations of apolipoprotein A-I lead to differentiated functional effects on lipid-binding and on glucose metabolism. Biochim Biophys Acta Mol basis Dis. 2018;9:23.

18.

Duan Y, Wu Z, Liu B. Relation of plasma glucose levels to serum lipids and apolipoproteins levels in middle and old age males. Hua Xi Yi Ke Da Xue Xue Bao. 2001;32(3):382–4.PubMed

19.

Retnakaran R, Ye C, Connelly PW, Hanley AJ, Sermer M, Zinman B. Serum apoA1 (Apolipoprotein A-1), insulin resistance, and the risk of gestational diabetes mellitus in human pregnancy-brief report. Arterioscler Thromb Vasc Biol. 2019;39(10):2192–7. https://doi.org/10.1161/ATVBAHA.119.313195.

20.

Makaridze Z, Giorgadze E, Asatiani K. Apolipoprotein B/apolipoprotein A-I ratio in relation to the metabolic syndrome, its components, total cholesterol and low-density lipoprotein cholesterol in the population of Georgia. Georgian Med News. 2014;234:32–9.

21.

Zhong L, Li Q, Jiang Y, Cheng D, Liu Z, Wang BQ, et al. The ApoB/ApoA1 ratio is associated with metabolic syndrome and its components in a Chinese population. Inflammation. 2010;33(6):353–8. https://doi.org/10.1007/s10753-010-9193-4.

22.

Mellor DD, Georgousopoulou EN, D'Cunha NM, Naumovski N, Chrysohoou C, Tousoulis D, et al. Association between lipids and apolipoproteins on type 2 diabetes risk; moderating effects of gender and polymorphisms; the ATTICA study. Nutr Metab Cardiovasc Dis. 2020;30(5):788–95. https://doi.org/10.1016/j.numecd.2020.01.008.

23.

Malyala R, Rapi L, Nash MM, Prasad GVR. Serum Apolipoprotein B and A1 concentrations predict late-onset Posttransplant diabetes mellitus in prevalent adult kidney transplant recipients. Can J Kidney Health Dis. 2019;6:2054358119850536.CrossRef

24.

Wu X, Yu Z, Su W, Isquith DA, Neradilek MB, Lu N, et al. Low levels of ApoA1 improve risk prediction of type 2 diabetes mellitus. J Clin Lipidol. 2017;11(2):362–8. https://doi.org/10.1016/j.jacl.2017.01.009.

25.

Hwang YC, Ahn HY, Park SW, Park CY. Association of HDL-C and apolipoprotein A-I with the risk of type 2 diabetes in subjects with impaired fasting glucose. Eur J Endocrinol. 2014;171(1):137–42. https://doi.org/10.1530/EJE-14-0195.CrossRefPubMed

26.

Hashemi M, Saadat M, Behjati M, Kelishadi R. Comparison of serum Apolipoprotein levels of diabetic children and healthy children with or without diabetic parents. Cholesterol. 2012;490381:3.

27.

Onat A, Komurcu-Bayrak E, Can G, Kucukdurmaz Z, Hergenc G, Erginel-Unaltuna N, et al. Apolipoprotein A-I positively associated with diabetes in women independently of apolipoprotein E genotype and apolipoprotein B levels. Nutrition. 2010;26(10):975–80. https://doi.org/10.1016/j.nut.2009.09.023.

28.

Chou YC, You SL, Bai CH, Liao YC, Wei CY, Sun CA, et al. Utility of apolipoprotein measurements in predicting incident type 2 diabetes: a Chinese cohort study. J Formos Med Assoc. 2020;119(1):51–8. https://doi.org/10.1016/j.jfma.2019.03.001.

29.

Zheng S, Han T, Xu H, Zhou H, Ren X, Wu P, et al. Associations of apolipoprotein B/apolipoprotein A-I ratio with pre-diabetes and diabetes risks: a cross-sectional study in Chinese adults. BMJ Open. 2017;7:2016–014038.

30.

Hwang YC, Ahn HY, Kim WJ, Park CY, Park SW. Increased apoB/A-I ratio independently associated with type 2 diabetes mellitus: cross-sectional study in a Korean population. Diabet Med. 2012;29(9):1165–70. https://doi.org/10.1111/j.1464-5491.2012.03622.x.CrossRefPubMed

31.

Pare G, Caku A, McQueen M, Anand SS, Enas E, Clarke R, et al. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. 2019;139(12):1472–82. https://doi.org/10.1161/CIRCULATIONAHA.118.034311.

32.

Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analyses for the global burden of disease study 2013. Lancet. 2014;384(9945):766–81. https://doi.org/10.1016/S0140-6736(14)60460-8.

33.

Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet. 2006;368(9548):1681–8. https://doi.org/10.1016/S0140-6736(06)69703-1.

34.

Butkowski EG, Jelinek HF. Hyperglycaemia, oxidative stress and inflammatory markers. Redox Rep. 2017;22(6):257–64. https://doi.org/10.1080/13510002.2016.1215643.CrossRefPubMed

35.

Su X, Peng D. The exchangeable apolipoproteins in lipid metabolism and obesity. Clin Chim Acta. 2020;503:128–35. https://doi.org/10.1016/j.cca.2020.01.015.CrossRefPubMed

36.

Zhang C, Ho S. Validity and reproducibility of a food frequency questionnaire among Chinese women in Guangdong province. Asia Pac J Clin Nutr. 2009;18(2):240–50.PubMed

37.

Dong HL, Tang XY, Deng YY, Zhong QW, Wang C, Zhang ZQ, et al. Urinary equol, but not daidzein and genistein, was inversely associated with the risk of type 2 diabetes in Chinese adults. Eur J Nutr. 2020;59(2):719–28. https://doi.org/10.1007/s00394-019-01939-0.

38.

Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51(6):1173–82. https://doi.org/10.1037/0022-3514.51.6.1173.CrossRefPubMed

39.

Chen W, Wu Y, Lu Q, Wang S, Xing D. Endogenous ApoA-I expression in macrophages: a potential target for protection against atherosclerosis. Clin Chim Acta. 2020;505:55–9. https://doi.org/10.1016/j.cca.2020.02.025.

40.

Mahley RW, Innerarity TL, Jr Rall SC, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984;25(12):1277–94. https://doi.org/10.1016/S0022-2275(20)34443-6.CrossRefPubMed

41.

Fruchart JC. Lipoprotein heterogeneity and its effect on apolipoprotein assays. Scand J Clin Lab Investig Suppl. 1990;198:51–7.CrossRef

42.

Francis MC, Frohlich JJ. Coronary artery disease in patients at low risk--apolipoprotein AI as an independent risk factor. Atherosclerosis. 2001;155(1):165–70. https://doi.org/10.1016/S0021-9150(00)00528-1.CrossRefPubMed

43.

Walldius G, Jungner I. Apolipoprotein A-I versus HDL cholesterol in the prediction of risk for myocardial infarction and stroke. Curr Opin Cardiol. 2007;22(4):359–67. https://doi.org/10.1097/HCO.0b013e3281bd8849.CrossRefPubMed

44.

Papachristou NI, Blair HC, Kypreos KE, Papachristou DJ. High-density lipoprotein (HDL) metabolism and bone mass. J Endocrinol. 2017;233(2):R95–R107. https://doi.org/10.1530/JOE-16-0657.

45.

Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS One. 2010;5:0010100.

46.

Brahimaj A, Ligthart S, Ikram MA, Hofman A, Franco OH, Sijbrands EJG, et al. Serum levels of Apolipoproteins and incident type 2 diabetes: a prospective cohort study. Diabetes Care. 2017;40(3):346–51. https://doi.org/10.2337/dc16-1295.

47.

Chen ES, Mazzotti DR, Furuya TK, Cendoroglo MS, Ramos LR, Araujo LQ, et al. Apolipoprotein A1 gene polymorphisms as risk factors for hypertension and obesity. Clin Exp Med. 2009;9(4):319–25. https://doi.org/10.1007/s10238-009-0051-3.

48.

Lappas M, Georgiou HM, Velagic A, Willcox JC, Permezel M, Shub A. Do postpartum levels of Apolipoproteins prospectively predict the development of type 2 diabetes in women with previous gestational diabetes mellitus? Exp Clin Endocrinol Diabetes. 2019;127(6):353–8. https://doi.org/10.1055/a-0577-7700.CrossRefPubMed

49.

Ley SH, Harris SB, Connelly PW, Mamakeesick M, Gittelsohn J, Wolever TM, et al. Association of apolipoprotein B with incident type 2 diabetes in an Aboriginal Canadian population. Clin Chem. 2010;56(4):666–70. https://doi.org/10.1373/clinchem.2009.136994.

50.

Hwang YC, Ahn HY, Yu SH, Park SW, Park CY. Atherogenic dyslipidaemic profiles associated with the development of Type 2 diabetes: a 3.1-year longitudinal study. Diabet Med. 2014;31:24–30.CrossRef

51.

Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Walldius G, Hamsten A, et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J. 2007;28(21):2637–43. https://doi.org/10.1093/eurheartj/ehm360.

52.

Fritzen AM, Domingo-Espín J, Lundsgaard AM, Kleinert M, Israelsen I, Carl CS, et al. ApoA-1 improves glucose tolerance by increasing glucose uptake into heart and skeletal muscle independently of AMPKα (2). Mol Metab. 2020;35:4.CrossRef

53.

Skogsberg J, Dicker A, Rydén M, Aström G, Nilsson R, Bhuiyan H, et al. ApoB100-LDL acts as a metabolic signal from liver to peripheral fat causing inhibition of lipolysis in adipocytes. PLoS One. 2008;3:20.CrossRef

54.

Watts GF, Ooi EM, Chan DC. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. Pharmacol Ther. 2009;123(3):281–91. https://doi.org/10.1016/j.pharmthera.2009.04.005.CrossRefPubMed

55.

Meriwether D, Sulaiman D, Volpe C, Dorfman A, Grijalva V, Dorreh N, et al. Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model. J Clin Invest. 2019;129(9):3670–85. https://doi.org/10.1172/JCI123700.

56.

Gabás-Rivera C, Barranquero C, Martínez-Beamonte R, Navarro MA, Surra JC, Osada J. Dietary squalene increases high density lipoprotein-cholesterol and paraoxonase 1 and decreases oxidative stress in mice. PLoS One. 2014;9(8):e104224. https://doi.org/10.1371/journal.pone.0104224.CrossRefPubMedPubMedCentral

57.

Lee JY, Kang MJ, Choi JY, Park JS, Park JK, Lee EY, et al. Apolipoprotein B binds to enolase-1 and aggravates inflammation in rheumatoid arthritis. Ann Rheum Dis. 2018;77(10):1480–9. https://doi.org/10.1136/annrheumdis-2018-213444.

58.

Mente A, Dehghan M, Rangarajan S, McQueen M, Dagenais G, Wielgosz A, et al. Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. Lancet Diabetes Endocrinol. 2017;5(10):774–87. https://doi.org/10.1016/S2213-8587(17)30283-8.

Title: Association of apolipoproteins A1 and B with type 2 diabetes and fasting blood glucose: a cross-sectional study
Authors: Liang Gao
Yaju Zhang
Xingmin Wang
Hongli Dong
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Type 2 Diabetes
Published in: BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/s12902-021-00726-5

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Association of apolipoproteins A1 and B with type 2 diabetes and fasting blood glucose: a cross-sectional study

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Highlights from the ACC 2024 Congress

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Psychometric evaluation of the Persian version of the diabetic foot self-care questionnaire in Iranian patients with diabetes

Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): a prospective non-interventional follow-up study

Understanding the role of oxidative stress in the incidence of metabolic syndrome and obstructive sleep apnea

Prediction model for the onset risk of impaired fasting glucose: a 10-year longitudinal retrospective cohort health check-up study

A novel heterozygous mutation of CHD7 gene in a Chinese patient with Kallmann syndrome: a case report

Developing a research database of primary aldosteronism: rationale and baseline characteristics

ACC 2024 Congress Coverage

Highlights from the ACC 2024 Congress

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page